clinical trial · NCT01725282
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
Major Depressive Disorderquetiapine extended release (XR)Placebo
brief summary
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and dose-response in three quetiapine XR dose groups based on changes in Montgomery-Asberg Depression Rating Scale (MADRS) scores.
started
Dec 14, 2011
primary completion
Aug 24, 2013
completion
Aug 24, 2013
last updated
Nov 15, 2024
official title
Phase 2 Study of FK949E - Double-blind, Placebo-controlled, Comparative Study in Major Depressive Disorder Patients With Inadequate Response to Existing Antidepressants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol